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Abstract
Background: Urokinase plasminogen activator (uPA) receptor (uPAR) is up-regulated at the invasive tumour front
of human oral squamous cell carcinoma (OSCC), indicating a role for uPAR in tumour progression. We previously
observed elevated expression of uPAR at the tumour-stroma interface in a mouse model for OSCC, which was
associated with increased proteolytic activity. The tumour microenvironment regulated uPAR expression, as well as
its glycosylation and cleavage. Both full-length- and cleaved uPAR (uPAR (II-III)) are involved in highly regulated
processes such as cell signalling, proliferation, migration, stem cell mobilization and invasion. The aim of the current
study was to analyse tumour associated factors and their effect on uPAR cleavage, and the potential implications
for cell proliferation, migration and invasion.
Methods: Mouse uPAR was stably overexpressed in the mouse OSCC cell line AT84. The ratio of full-length versus
cleaved uPAR as analysed by Western blotting and its regulation was assessed by addition of different protease
inhibitors and transforming growth factor - β1 (TGF-β1). The role of uPAR cleavage in cell proliferation and migration
was analysed using real-time cell analysis and invasion was assessed using the myoma invasion model.
Results: We found that when uPAR was overexpressed a proportion of the receptor was cleaved, thus the cells presented
both full-length uPAR and uPAR (II-III). Cleavage was mainly performed by serine proteases and urokinase plasminogen
activator (uPA) in particular. When the OSCC cells were stimulated with TGF-β1, the production of the uPA inhibitor PAI-1
was increased, resulting in a reduction of uPAR cleavage. By inhibiting cleavage of uPAR, cell migration was reduced, and
by inhibiting uPA activity, invasion was reduced. We could also show that medium containing soluble uPAR (suPAR), and
cleaved soluble uPAR (suPAR (II-III)), induced migration in OSCC cells with low endogenous levels of uPAR.
Conclusions: These results show that soluble factors in the tumour microenvironment, such as TGF-β1, PAI-1 and uPA, can
influence the ratio of full length and uPAR (II-III) and thereby potentially effect cell migration and invasion. Resolving how
uPAR cleavage is controlled is therefore vital for understanding how OSCC progresses and potentially provides new targets
for therapy.
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Background
Oral squamous cell carcinoma (OSCC) is characterized
by aggressive behaviour, including local invasion and
metastasis to lymph nodes [1, 2]. Expression of the uro-
kinase plasminogen activator (uPA) receptor (uPAR) has
been reported to be elevated at the tumour-stroma
border of many cancer types [3–5], including OSCC
[6, 7], indicating a role of uPAR in cancer invasion.
uPAR is involved in binding and activation of the pro-
tease uPA. Once activated, uPA can proteolytically cleave
plasminogen, producing the active broad spectrum serine
protease plasmin needed in normal physiological pro-
cesses such as wound healing [8]. In a feedback-loop fash-
ion, plasmin activates uPA, but also several matrix
metalloproteases (MMPs) and growth factors. Plasmin
may be inhibited by α2-antiplasmin, α2-macroglobulin,
thrombin activatable fibrinolysis inhibitor (TAFI) and pro-
tease nexin-1 (PN-1), while uPA is inhibited mainly by
plasminogen activator inhibitor-1 (PAI-1) and −2 (PAI-2)
[8, 9]. Higher levels of uPA, uPAR and PAI-1 correspond
to more aggressive disease for prostate-, cervical-, liver-
and oral cancer [8], where uPA and PAI-1 have been vali-
dated as strong and independent prognostic factors for
poor survival in primary breast cancer [10]. We recently
reported that low expression of uPAR and PAI-1, was cor-
related with longer disease specific survival in early stage
OSCC [11]. Furthermore, one of the key regulators of
PAI-1 expression, transforming growth factor β1 (TGF-
β1), is increased in pre-malignant oral leukoplakia and in
OSCC compared to normal oral mucosa [12, 13].
uPAR is GPI-anchored to the cell membrane and
hence locates proteolytic activity to the cell surface,
which is needed for the invasive process, as seen during
wound healing and cancer invasion [14, 15]. Both hu-
man and murine uPAR consists of a single polypeptide
chain that forms a 3D structure consisting of three hom-
ologous domains, known as domains I, II and III, where
the GPI-anchor is attached to the third domain. These
three domains create an internal cavity where pro-uPA
can bind via its amino terminal fragment (ATF) and be-
come activated [16–18]. Once activated, uPA, along with
a spectrum of other proteases, including plasmin,
chymotrypsin, cathepsin G, elastase and MMP’s [19–22],
can cleave uPAR creating a shorter protein containing
only domains II and III, termed uPAR (II-III) [23]. uPA-
induced cleavage renders uPAR (II-III) on the cell sur-
face, now unable to bind uPA [24, 25]. Even though
uPAR lacks an intracellular domain, the receptor is in-
volved in cell signalling, mainly through the interaction
with neighbouring receptors [26], where full-length
uPAR and uPAR (II-III) engage different signalling path-
ways [27]. uPAR can also be shed from the cell surface,
producing soluble variants of uPAR, namely full-length
soluble uPAR (suPAR) or cleaved soluble uPAR; suPAR
(II-III) [28] and suPAR (I). These uPAR fragments are
correlated with survival in many cancer types [29–32]
and several studies indicate that uPAR (II-III) and suPAR
(II-III) are involved in highly regulated processes such as
cell signalling [28] and stem cell mobilization [33, 34].
Today, little is known about how uPAR cleavage is
regulated and the consequences this has on cancer pro-
gression. We recently showed that the tumour micro-
environment (TME), mainly through soluble factors,
readily up-regulated the expression and cleavage of
uPAR in mouse OSCC cells [35]. The TME consists of
different cell types such as immune cells, endothelial
cells and fibroblasts, as well as structural matrix pro-
teins, insoluble and soluble factors such as cytokines,
chemokines and growth factors, including TGF-β1 [36].
TGF-β1 is a fundamental regulatory molecule of the
tumour microenvironment and may be expressed by
tumour-associated macrophages (TAMs), cancer-associated
fibroblasts (CAFs) and cancer cells [37–39].
The aim of the current study was to analyse the regu-
lation of uPAR expression and cleavage by uPA and
TGF-β1, and the potential implications on migration
and invasion of the mouse OSCC cells AT84. We found
that TGF-β1 reduced uPAR cleavage through up-
regulation of PAI-1 expression, increasing the amount of
full-length uPAR present on the AT84 OSCC cells. Both
cell surface associated- and shed uPAR (suPAR and
suPAR (II-III)) were found to regulate cell migration and
invasion. Inhibiting uPA activity, and thus uPAR cleav-
age, with the uPA-specific inhibitor BC11 hydrobromide,
resulted in reduced migration and invasion. In conclu-
sion, these results demonstrate that the ratio of full-
length versus cleaved uPAR can be regulated by TGF-β1,




Bovine serum albumin (BSA) (A9647, lot: SLBC9771V),
aprotinin from bovine lung (A3428, lot: 060M70081V),
NaHCO3-buffered RPMI-1640 with L-glutamine (R8758),
Dulbecco’s Modified Eagle Medium (DMEM; D5796),
foetal bovine serum (FBS) (F7524, lot: 011 M3398), puro-
mycin dihydrochloride (P9620), DL-Dithiothreitol (DTT)
(43,815, lot: BCBK8939V), SIGMAFAST™ Protease Inhibi-
tor Cocktail (S8830-20TAB, lot: SLBG7024V), penicillin
and streptomycin mix (P4333), the TGF-β1 inhibitor
SB431542 (S4317, lot: 104M4747V) were purchased from
Sigma Aldrich (St. Louis, MO, USA). The QIAshredder
kit (79654), RNeasy kit (74134), QuantiTect Reverse Tran-
scription Kit (205313) and primers (uPAR: QT00102984,
uPA: QT00103159, Plasminogen: QT01053332, βactin:
QT00095242, and TRFC: QT00122745) were purchased
from Qiagen (Hilden, Germany). The Faststart Essential
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DNA Green Master (06402712001) was purchased from
Roche Diagnostics (Indianapolis, IN). The Direct Detect
system (DDAC00010-GR, lot: 39,591–1-9), PVDF mem-
branes (IPVH00010), Re-Blot Plus Mild Solution (2502)
were all from EMD Millipore Corp. (Billerica, MA). BC11
hydrobromide (4372, Batch no. 1A/117980) was pur-
chased from Tocris Bioscience (Ellisville, MO) and
TGF-β1 (100-B-001, lot: A5013041) from RD Systems
(Minneapolis, MN). Recombinant murine PAI-1 (rmPAI-
1) (528,213, Lot: D00138824) was purchased from
Calbiochem, EMD Chemicals Inc. (San Diego, CA). Puri-
fied mouse high molecular weight (HMW)-uPA (MUPA)
and mouse plasmin (MPLM) were from Molecular Inno-
vations (Novi, MI). Plasminogen (plg) from human plasma
(528,175, Lot: D00156550) was purchased from Merck
KGaA (Darmstadt, Germany). The Gateway® cloning sys-
tem and the Bis-Tris SDS-gels were bought from Invitro-
gen (Carlsbad, CA). EDTA (20,302.293, lot: 09 K26007)
was purchased from VWR International (Leuven, Belguim).
Opti-MEM (31985–047) was purchased from Gibco
(Paisley, UK). The PNGase F kit (P0704S) was from New
England BioLabs (Beverly, MA). Biotinylated protein ladder
(7727, lot: 21) was from Cell Signaling Technology
(Danvers, MA). Western blotting Luminol Reagent (sc-
2048) was from Santa Cruz Biotechnology Inc. (Frederick,
MD). The polink-2 Plus HRP Detection kit for goat primary
antibody was from GBI Labs (Mukilteo, WA). The follow-
ing machines and software were purchased as follows: SPSS
Statistics 19 for Windows from SPSS Corp. (Chicago, Il),
CDF320 camera, DCF425 camera, IM50 software, Leica
Application Suite (LAS version 3.7.0) from Leica Microsys-
tems (Heerburg, Switzerland), SigmaPlot from Systat
Software Inc. (London, UK) and Olympus DP software, Soft
5.0 (Olympus Corporation, Tokyo, Japan). The LightCycler
96 and the xCELLigence system were from Roche Diagnos-
tics (Mannheim, Germany), LAS-3000 imaging system was
from Fujifilm (Tokyo, Japan). The NanoDrop spectropho-
tometer was from Thermo Scientific (Wilmington, DE), the
Experion automated electrophoresis system was from Bio-
Rad Laboratories (Hercules, CA). The BD FACSAria was
from BD Biosciences (San Jose, CA), and FlowJo software
(version 7.6.5) was from Tree star Inc. (Ashland, OR).
Antibodies
Antigen affinity-purified polyclonal goat anti-mouse uPAR
antibody (AF534, lot no: DCL03112081, DCL0311021)
was from R&D Systems (Minneapolis, MN). We have pre-
viously demonstrated the antibody specificity in IHC [35].
For Western blotting a dilution 1:1000 or 1:500 was used.
To demonstrate the specificity of AF534 in Western blots,
a sheep anti-mouse uPAR antibody (CSI19991A, lot no:
2,209,001) from Cell Sciences (Canton, MA) was used in a
Western blot at 1:2500 dilution and similar results were
obtained (results not shown). In flow cytometer analysis,
AF534 was used in 1:100 dilution, and for immunohisto-
chemistry (IHC) a 1:200 dilution for 1 h at room
temperature. For flow cytometry, the Alexa Fluor 488
donkey anti-goat antibody (A11055) from Invitrogen
(Carlsbad, CA) was used at 1:500. For Western blotting,
HRP-conjugated anti goat/sheep (A9452) was used at
1:100,000, and HRP-conjugated anti-β-actin (A3854) at
1:25,000 (Sigma Aldrich, St. Louis, MO). The polyclonal
rabbit anti-murine PAI-1 antibody was used for neutraliz-
ing murine PAI-1 (50 μg/ml) and for Western blotting at
1:2500 (Ab28207, lot no: 1,060,006) was from Abcam Inc.
(Cambridge, MA). Monoclonal rabbit anti-low density
LPR (LRP1)(EPR3724, lot no GR47571–2) was diluted
1:2500 (ab92544, Abcam Inc., Cambridge, MA) and both
were detected using HRP-conjugated anti-rabbit (4050–05,
Southern Biotech, Birmingham, AL). To enable detection
of the biotinylated protein ladder, an anti-biotin HRP-
linked antibody was used at 1:1000 dilution (7075P5, lot:
30, Cell Signaling Technology, Danvers, MA).
Cloning and expression of uPAR in cultured AT84 cells
Cloning of uPAR in AT84 cells has previously been de-
scribed [35], but is summarized in brief. The Plaur gene
was cloned from the murine macrophage cell line J774
into the mouse cell line AT84 using the Gateway® clon-
ing system. Overexpression of uPAR was achieved
through stable transfection of pDest/TO/PGK-puro/
uPAR and a mixed population was obtained through
puromycin treatment. Using Fluorescence-activated cell
sorting (FACS), 11.000 cells expressing high levels of
uPAR were sorted for further culturing and denoted
AT84-uPAR (see flow cytometry below). Control cells
containing only the empty vector, pDest/TO/PGK-puro,
were denoted AT84-EV cells. Cell images were recorded
using a Leica camera and the IM50 software.
Cell lines
The mouse tongue SCC cell line AT84, originally
isolated from a C3H mouse [40], was kindly provided by
Professor Shillitoe, Upstate Medical University, Syracuse,
NY [41]. All cells were cultured at 37 °C, 5% CO2 in a
humid environment. AT84 cells were maintained in
RPMI, supplemented with 10% FBS. For AT84 cells
overexpressing uPAR, the culture medium was supple-
mented with 5 μg/ml puromycin.
Conditioned medium
Eight ml serum free medium (SFM; RPMI-1640) was
added to AT84-EV and AT84-uPAR cells at 60–70%
confluency in 75 cm2 culture flasks. The medium was
conditioned for 48 h. When analysing for suPAR, the
conditioned medium from the AT84-EV and the AT84-
uPAR cells was concentrated from 2 ml to an equal final
volume (specified in the figure legend) using the Vivaspin
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500, membrane 10,000 MWPO PES. Conditioned medium
containing the soluble factors from the tumour microenvir-
onment (TMEM) of the neoplastic leiomyoma tissue was
harvested as previously described [35].
Flow cytometry
Cells were seeded in medium containing 10% FBS and
incubated for 24 h, whereupon the medium was ex-
changed for SFM and the cells incubated for another
24 h. Cells were detached with 1 mM EDTA and washed
once in RPMI w/10% FBS. All subsequent washing steps
were performed with Opti-MEM containing 1% BSA,
and blocking was done with Opti-MEM w/5% BSA.
Non-permeablized cells were labelled using the 1:100
goat polyclonal anti-murine uPAR antibody and 1:1000
Alexa Fluor 488 donkey anti-goat secondary antibody in
Opti-MEM w/1% BSA. Cells were subsequently analysed
and sorted using a BD FACSAria. For each sample,
10,000 cells were gated. Figures were designed using
FlowJo.
Induction and inhibition of uPAR cleavage
Cells were detached using trypsin (0.25% in PBS with
0.05% Na2EDTA), counted and equal cell numbers were
seeded in serum-containing media and incubated for
24 h. Cells were then treated in an assay specific man-
ner. Culture medium was exchanged for either SFM or
culture medium containing 10% FBS (FBSM). Aprotinin
(1.6 mM dissolved in water), BC11 hydrobromide
(100 mM dissolved in DMSO. Previously specificity
tested [35]), TGF-β1 (10 μg/ml dissolved in 4 mM HCl
with 1% BSA) and rmPAI-1 (60.5 μM dissolved in
100 mM NaCl, 50 mM sodium acetate, 1 mM EDTA,
pH 5.0) were added to the culture medium to a final and
optimized concentration specified in the figure legends
and indicated in the figures. TGF-β1 signalling was
inhibited by adding either 2 ng/ml TGF-β1 and/or
10 μM of the specific TGF-β1 inhibitor SB431542.
Conditioned medium and cell lysates were prepared by
removing or harvesting the culture media and scraping
cells in RIPA buffer (25 mM Tris-HCl, pH 7.6,
150 mM NaCl, 1% Triton-X100, 0.5% sodium deoxy-
cholate, 0.1% SDS) containing 1× SIGMAFAST™
Protease Inhibitor Cocktail.
Antibody mediated PAI-1 blocking
Cells were seeded as described in the previous section
and treated with 2 ng/ml TGF-β1 in FBSM. Cells were
simultaneously treated with 50 μg/ml of the anti-PAI-
1 antibody (Ab28207) and incubated for 24 h. Con-
trols received either no treatment, or only TGF-β1.
Cells were harvested as described in the “Induction
and inhibition of uPAR cleavage” section and analysed
by Western blotting.
Deglycosylation by PNGase F treatment
Cell lysates were treated with PNGase F to remove all
N-linked glycosylation. The procedure was performed
according to the manufacturer’s protocol with some ad-
justments. In brief, 1× denaturing buffer was added to
the cell lysate or conditioned medium and boiled for
10 min. 1× G7 reaction buffer, 1% NP-40 and 0.5 μl
PNGase F were added and incubated for 1 h at 37 °C.
Samples were then analysed by SDS-PAGE and Western
blotting.
Western blotting
Cells lysates were sonicated, reduced and boiled. Condi-
tioned medium was neither reduced nor boiled. Total
protein concentration was assessed using the Direct
Detect system. Some samples were deglycosylated using
PNGase F, before equal amounts of protein (10–30 μg)
were loaded onto NuPAGE Novex 4%–12% Bis-Tris gels,
and subjected to non-reducing SDS-PAGE. A biotinyl-
ated protein ladder was run on all gels. Proteins were
blotted onto PVDF membranes. Blocking was done with
5% non-fat dry milk, or 5% BSA, in Tris-buffered saline
(150 mM NaCl, 20 mM Tris, pH 7.4) supplemented with
0.1% Tween 20. Membranes were incubated with the
specific primary antibody at 4 °C overnight diluted in
blocking buffer. A HRP-conjugated species specific sec-
ondary antibody was used to detect the primary anti-
body. Western blotting Luminol Reagent was used for
antibody detection. Equal loading was controlled by re-
probing for β-actin. Images were obtained using the
LAS-3000 imaging system.
Reverse transcriptase quantitative PCR (RT-qPCR)
Cultured cells (3.0 × 105 cells) were harvested using
300 μl RTL buffer containing 100 mM DTT. Samples
were homogenized using the QIAshredder followed by
total RNA extraction using the RNeasy kit. Quantity and
purity of the extracted RNA was determined using the
NanoDrop. RNA integrity is routinely assessed on ran-
dom samples using the Experion automated electrophor-
esis system. mRNA expression levels were analysed
using reverse transcription quantitative PCR (RT-qPCR)
on a LightCycler 96. cDNA was synthesized from 1 μg
total RNA using the QuantiTect Reverse Transcription
Kit. Target cDNA, corresponding to 10 ng RNA, was
amplified through 40 cycles in a 25 μl qPCR mix con-
taining 1 μl Qiagen primer mix for uPAR (QT00102984),
uPA (QT00103159), Plasminogen (QT01053332), βactin
(QT00095242) or TRFC (QT00122745) and FastStart
Essential DNA Green Master mix. A dissociation curve
was routinely run at the end of every PCR to verify sam-
ple purity, primer specificity and absence of primer di-
mers. qPCR cycling conditions: Step 1: 95 °C for 10 min.
Step 2: 95 °C for 10 s, 60 °C for 10 s and 72 °C for 10 s
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was repeated 45 times. Step 3 (dissociation curve): 95 °C
for 10 s, 65 °C for 60 s and 97 °C for 1 s continuously.
Absence of genomic DNA and contaminants was con-
firmed by performing no reverse transcriptase (NoRT)
controls with every round of RNA purification, and non-
template controls (NTC) on each primer set, respect-
ively. For each experiment RNA was purified from at
least three biological replicates (N = 3). Reverse tran-
scription was performed on all biological replicates, and
each biological replicate was loaded as two technical
replicates per RT-qPCR run. The delta-delta Cq method
[42] was used to determine the relative amount of target
mRNA in samples normalized against the average ex-
pression of the two reference genes Trfc and βactin. The
numbers are presented as fold differences where the
lowest value is set to 1.
Gelatin- and plasminogen-gelatin zymography
Cells were seeded and incubated overnight and washed
three times in PBS before the medium was exchanged
for SFM, harvested after 24 h and spun down to remove
any cells. MMP-2 and MMP-9, as well as uPA and plas-
minogen levels were assessed by gelatin (gelzym) and
combined gelatin-plasminogen zymography (plgzym) re-
spectively, as previously described [43]. When analysing
plasminogen activators, a final concentration of 10 μg/
ml of plasminogen was added to the gel. As controls,
purified mouse HMW-uPA (44 kDa), mouse plasmin
(mPLM, 85 kDa), trypsin (24 kDa) and a mixture of both
inactive pro-form and active-form of both human
MMP-2 monomer (62 and 72 kDa) and MMP-9 mono-
mer (83 and 92 kDa) were used.
Real-time cell analysis
The xCELLigence system and real-time cell analysis
(RTCA) was used to determine the proliferation and migra-
tory capacity of the cells according to the manufacturer’s
instructions. Proliferation experiments were performed to
determine the optimal cell seeding density (100–300,000
cells), and for both proliferation- and migration studies a
total of 30,000 cells were selected for seeding in 100 μl
medium. All experiments were performed at least three
times (N = 3), and two technical replicates were included
per experiment.
Proliferation
Thirty μl SFM was added to the E-plates and a back-
ground reading was performed. Cells were detached
using trypsin (0.25% in PBS with 0.05% Na2EDTA),
counted and seeded. Attaching and proliferating cells
were recorded by electrical impedance, measured every
15 min by the electrodes in the bottom of the wells
giving the arbitrary “cell index” value, proportional to
the cell number. Cell proliferation was assessed on cells
seeded in FBSM as a control, or supplemented with
BC11 hydrobromide (10 μM), rmPAI-1 (10 nM) or
TGF-β1 (2 ng/ml = 167pM) for at least 72 h.
Migration
The bottom wells of cell invasion and migration (CIM)
plates were loaded with 160 μl FBSM, with or without
the presence BC11 hydrobromide (10 μM), rmPAI-1
(10 nM) or TGF-β1 (2 ng/ml = 167pM). For the suPAR
chemotaxis experiments the bottom chamber was filled
with 160 μl of AT84-EV or AT84-uPAR conditioned
medium. A top chamber containing 16 wells, each
equipped with an 8 μm pore membrane in the bottom
was then mounted onto the bottom chamber. The wells
in the top chamber were loaded with 25 μl SFM, and the
plate was equilibrated for 1 h at 37 °C, 5% CO2, in a
humid environment. A background measurement was
performed before cells, re-suspended in SFM (with or
without inhibitors), were loaded into the wells. Cells
were allowed to attach to the well for 15 min at room
temperature, before the plate was mounted into the
xCELLigence machine. Electrodes located underneath
the membrane recorded only the migrating cells for the
subsequent 72 h. Electrical impedance was measured
every 15 min and translated into the arbitrary “cell
index” value, proportional to the cell number.
Organotypic invasion model
Preparation of the leiomyoma discs and the invasion
procedure has previously been described in detail [35].
In brief, discs of freeze-dried benign leiomyoma tumour
tissue were rehydrated in SFM overnight. A total of
0.4 × 106 cells suspended in 50 μl SFM were seeded on
top of the discs, and three discs were used per cell line
(N = 3). Cells were allowed to attach and invade the
tissue for seven days. Discs were fixed in a zinc-based
fixative (ZBF) (36.7 mM ZnCl2, 27.3 ZnAc2, x2H2O
and 0.63 mM CaAc2 in 0.1 mol/L Tris pH 7.4), dehy-
drated and paraffin-embedded. Tissue sections of the
leiomyoma discs were stained with hematoxylin/eosin
(H/E) and a blinded analysis of cell invasion was per-
formed on images using the Olympus DP software,
Soft 5.0. A horizontal line was drawn through the
uppermost remnants of the leiomyoma tissue in order
to set a “basement membrane” level. Invasion depth
was determined every 100 μm along the horizontal
line as the vertical distance from this line to the limit
of invading cells. At least 6 measurements were per-
formed per tissue disc. Leiomyoma tissue without
added cells were used as negative controls. Images
were recorded using the Leica DCF425 camera and
the Leica Application Suite.
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Immunohistochemistry (IHC)
For analysis of uPAR expression, the ZBF fixed leio-
myoma discs were IHC stained as previously described
[35]. In brief, the primary antibody was diluted in 5%
BSA in PBS. For visualization of the uPAR primary anti-
body, the Polink-2 Plus HRP Detection kit for goat
primary antibody was used. The chromogen diamino-
benzidine (DAB) was used to visualize the secondary
HRP-linked antibody. Sections in which the primary
antibody was replaced with 5% BSA were used as nega-
tive controls and showed no staining. The specificity of
the anti-uPAR antibody has previously been verified for
IHC [35].
Statistical analysis
Data are presented as mean values ± standard deviation
(±SD) or ± standard error of mean (±SEM), specified in
the figure legends. The differences between groups were
assessed using independent-samples T-test. P-values
<0.05 were accepted as statistically significant. Graphics
were made using Excel and Sigma Plot. Statistical ana-
lyses were performed using SPSS. Independent repli-
cates (N) for the different data are presented in the
figure legends.
Results
Active uPA and plasmin are responsible for the majority
of uPAR cleavage
To follow up our findings from a previous in vivo study
[35], the mouse OSCC cell line AT84 was selected also
for this study. It enables us the use of a syngeneic mouse
model for OSCC in vivo, this being important as there is
no species cross-reactivity between human and mouse
uPA and uPAR [17]. Furthermore, the AT84 cells ex-
press low endogenous levels of uPAR in culture [35].
AT84 cells were stably transfected to overexpress mouse
uPAR, and bulk populations of both AT84-uPAR and
the empty vector transfected cells (AT84-EV) were gen-
erated. The AT84-uPAR cells expressed excess amounts
of uPAR protein compared to the AT84-EV cells (Fig. 1a),
and the receptor was exposed on the cell surface (Fig. 1b).
The AT84-uPAR cells expressed approximately 8-fold
more uPAR mRNA compared to the AT84-EV cells as
analysed by RT-qPCR (Fig. 1c, left panel). No statistically
significant difference in uPA mRNA expression levels
could be detected between EV- and uPAR expressing cells
(Fig. 1c, right panel). Plasminogen (plg) mRNA levels were
also analysed using RT-qPCR, but the expression level was
below the limit of detection.
Plasmin, uPA and some MMP’s including MMP-2 and
MMP-9 are reported to cleave uPAR [21, 23, 44]. To assess
the secreted levels of MMP-2, −9, plasmin and uPA in the
conditioned medium of the AT84-EV and AT84-uPAR
cells, gelatin zymography (gelzym)(results not shown) and
plasminogen-gelatin zymography (plgzym)(Fig. 1d) experi-
ments were performed. Murine plasmin (mPLM) was
loaded as a control, and the 85 kDa active plasmin is
indicated by an arrow. Plasmin can undergo auto-
proteolysis, as seen by the extra band (black arrow-
head). Plasmin was not detected in the conditioned
medium from the cells (Fig. 1d). As previously re-
ported, both AT84-EV and AT84-uPAR cells expressed
detectable levels of a plasminogen activator with the
same MW as HMW-uPA (white arrowhead) [35]. The
AT84-EV cells did in addition secrete an unknown plas-
minogen activator (asterisk), which the AT84-uPAR-
cells did not secrete. The AT84-EV and AT84-uPAR
cells did not secrete any detectable gelatin-degrading
enzymes, such as MMP-2 or MMP-9, as analysed by
gelzym (results not shown). Taken together, the AT84-
EV and -uPAR cells secreted active uPA, but not plas-
min, MMP-2 or MMP-9.
Increased expression of uPAR has been reported to
alter the morphological appearance of cells in culture
and induce epithelial-to-mesenchymal transition (EMT)
in breast cancer cells [45–48]. We found that AT84-uPAR
cells displayed a more elongated mesenchymal-like
morphology compared to the AT84-EV cells (Fig. 1e).
However, we did not pursue this further.
Human uPAR can be cleaved between domains I and
II, mainly by uPA and plasmin, but also by other prote-
ases [19, 21, 49]. This cleavage releases domain I and
leaves a cleaved version of uPAR on the cell surface
known as uPAR (II-III). Culturing the AT84-uPAR cells
in either serum free medium (SFM) or culture medium
containing 10% FBS (FBSM) gave uPAR bands of a
slightly different appearance on Western blots (Fig. 1a
and Fig. 1f, lane 1 and 3; uPARglc). When the cell lysates
were de-glycosylated using PNGase F (Fig. 1f, lane 2 and
4) it was apparent that uPAR was present both in its
cleaved (uPARII-III) and full-length version (uPARI-III) as
we have also previously reported [35]. As seen in Fig. 1f,
the FBSM induced a higher ratio of cleaved uPAR com-
pared to full-length uPAR than SFM. FBS contains many
different soluble factors that may induce uPAR cleavage
including plasminogen, which may be activated by the
uPA produced by the cells. Adding the previously tested
[35] specific uPA inhibitor BC11, or the serine protease
inhibitor aprotinin, to cells cultured in FBSM resulted in
a shift towards more full-length uPAR (Fig. 1g). Accord-
ingly, adding human plasminogen to cells cultured in
SFM tilted the ratio towards more cleaved uPAR (Fig. 1h).
Addition of recombinant murine PAI-1 (rmPAI-1) also
efficiently inhibited uPAR cleavage in FBSM (Fig. 1i), while
galardin, a broad-spectrum matrix metalloproteinase
(MMP) inhibitor, had no effect on uPAR cleavage in these
cells (results not shown). Taken together, these results
show that uPA and plasmin are the main regulators of the
Magnussen et al. BMC Cancer  (2017) 17:350 Page 6 of 16
Fig. 1 (See legend on next page.)
Magnussen et al. BMC Cancer  (2017) 17:350 Page 7 of 16
balance between cleaved and full-length uPAR on the cell
surface of AT84 cells. However, additional factors may
also play a role since the balance between cleaved and
full-length uPAR could not be completely shifted in either
direction.
TGF-β1 reduces uPAR cleavage through induced PAI-1
expression
We recently reported that medium containing soluble
factors from the tumour microenvironment (TMEM) of
the neoplastic leiomyoma tissue were the main regula-
tors of both glycosylation and cleavage of uPAR [35],
where TGF-β1 was found to be a major constituent of
the soluble TME fraction [50]. To analyse whether TGF-
β1 was one of the regulators of the observed uPAR
cleavage, AT84-uPAR cells were treated with 2 ng/ml ac-
tive recombinant human TGF-β1 for 24 h in FBSM.
TGF-β1 induced a clear shift towards more full-length
uPAR (Fig. 2a), confirming a role of TGF-β1 in regu-
lating uPAR cleavage. In contrast to previous reports
[51, 52], this shift was not due to a large increase in
uPAR mRNA expression (Fig. 2b; not significant), nor
as a result of decreased mRNA expression of the main
uPAR cleaver uPA (Fig. 2c; not significant).
uPA is inhibited by PAI-1, a well-known down-stream
target of TGF-β1 [53–57]. We therefore wanted to test
whether TGF-β1 could induce PAI-1 expression in the
AT84 cells, and thus inhibit uPA activity and uPAR
cleavage. The AT84-EV and AT84-uPAR cells were
cultured with SFM +/− TGF-β1 or FBSM +/− TGF-β1.
As a control, the cells were also cultured in SFM or
FBSM containing the buffer used for dissolving TGF-β1.
A well without cells, but with FBSM +/− TGF-β1, was
included as a negative control. After 24 h of incubation,
the medium was analysed for the presence of PAI-1 by
Western blotting (Fig. 2d). As expected, TGF-β1 induced
PAI-1 expression in the AT84-EV and AT84-uPAR cells
in both SFM and FBSM. There was also a slight differ-
ence in the MW of the PAI-1 band when the cells were
grown in SFM compared to when FBS was present.
Taken together, this shows that TGF-β1 is able to induce
PAI-1 expression in both AT84-EV and AT84-uPAR re-
gardless of the presence of FBS.
In order to verify that this effect was indeed mediated
by TGF-β1, treatment with the specific TGF-β1 inhibitor
SB431542 completely abolished the TGF-β1-induced
PAI-1 expression in the AT84-uPAR (Fig. 2e). To test
whether TGF-β1 had in fact reduced uPAR cleavage
through increased PAI-1 expression, an anti-PAI-1 anti-
body was added to AT84-uPAR cells stimulated with
TGF-β1 (Fig. 2f ). The blocking antibody resulted in a
shift towards more cleaved uPAR relative to full-length
uPAR. To further verify these results, we could also
show that inhibiting TGF-β1 signalling using SB431542
resulted in more uPAR cleavage in AT84-uPAR cells
compared to controls stimulated with only TGF-β1 in
SFM (Fig. 2g).
Low-density lipoprotein receptor-related protein 1
(LRP1) is an endocytic receptor for uPAR [58]. As re-
ported by others, once PAI-1 binds uPAR-bound uPA,
the uPAR/uPA/PAI-1 complex is endocytosed via LRP1,
and full-length uPAR is rapidly recycled back to the cell
surface [58, 59]. Different LRP1 levels might influence
the amount of uPAR, uPA and PAI-1, which again could
influence uPAR cleavage. Thus, we tested whether the
different growth media would influence the level of
LRP1. AT84-uPAR cells were cultured in either SFM,
FBSM, TMEM or TGF-β1 and lysates were analysed by
Western blot for LRP1 (Fig. 2h). Equal amounts of LRP1
could be detected in lysates from AT84-uPAR cells
regardless of growth medium and stimulation with TGF-
β1. The anti-LRP antibody recognizes an additional pro-
tein of a lower MW in samples containing FBS (black
arrowhead). The identity of this protein is unknown.
Thus, the difference in cleavage of uPAR is not due to
different levels of LRP1.
Taken together, these results show that TGF-β1 can
increase PAI-1 expression in the AT84 cells and thus re-
duce cleavage of uPAR, most likely via inhibition and in-
ternalization of uPA.
(See figure on previous page.)
Fig. 1 uPAR cleavage is mediated by plasmin and uPA. AT84 cells stably transfected with either empty vector (EV)(AT84-EV) or a vector containing cDNA
encoding mouse uPAR (AT84-uPAR) were analysed for uPAR mRNA and protein levels, secreted plasminogen activators and uPAR cleavage by Western
blotting of whole cell lysates (A, F-I), flow cytometry (B), RT-qPCR (C) and plasminogen-gelatin zymography (plgzym)(D). a. AT84-uPAR (uPAR) or AT84-EV
(EV) cells cultured in either serum-free medium (SFM) or medium containing 10% foetal bovine serum (FBSM) for 24- and 48 h. b. Non-permeabilized
AT84-EV (pink: median fluorescence 371) and AT84-uPAR (purple: median fluorescence 853) cells. Negative control with no primary antibody added (filled
curve). c. Relative uPAR mRNA (left panel) or uPA mRNA (right panel) expression levels. Error bars represent the standard deviation (+SD) and N = 3. Student
T-test; * p < 0.05. d. Conditioned medium from cells cultured for 24- and 48 h in SFM. Positive control: mPLM (mouse plasmin). Active mouse plasmin
(arrow), auto-proteolytic fragment of plasmin (black arrowhead), HMW-uPA (white arrowhead), and an unknown plasminogen activator (asterisk). e. Images
of AT84-EV and AT84-uPAR cells in culture 24 h after seeding (10× magnification). f-i. Whole cell lysates of AT84-uPAR cells treated with PNGase F (+) or no
PNGase F (−). f. Cells cultured in either FBSM or SFM. Glycosylated uPAR (uPARglc), deglycosylated samples gave rise to full length uPAR (uPARI-III) and
cleaved uPAR (uPARII-III). g. Cells cultured for 24 h in FBSM (0), or FBSM supplemented with either 1.5 μM, 8 μM or 15 μM aprotinin, or 10 μM BC11
hydrobromide. h. Cells cultured for 24 h either in SFM without plasminogen (0), or in SFM supplemented with 1 nM, 10 nM or 100 nM plasminogen.
i: AT84-uPAR cells cultured for 24 h in FBSM supplemented with 1-, 5-, 10- or 50 nM rmPAI-1. Controls (0 nM) received no additives
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Inhibition of uPA-activity reduces cell migration and invasion
in a uPAR-dependent manner
In order to analyse the functional effects of high levels
of uPAR in AT84 cells, a real-time cell proliferation
assay was performed in FBSM (Fig. 3a). Fold differences
in cell index values from 24- and 48 h from three indi-
vidual experiments were compared (Fig. 3b). AT84-
uPAR cells gave a cell index value that was higher than
that obtained from AT84-EV cells, suggesting a slightly
higher proliferative rate. At 24- and 48 h, the fold differ-
ence in proliferation between the two cell lines was
constant at 1.3 and statistically significant (p < 0.001) at
48 h (Fig. 3b).
Both full-length and cleaved human uPAR have been
reported to play a role during cancer cell migration [28].
Hence, the AT84-EV and AT84-uPAR cells were ana-
lysed for their ability to migrate using FBSM as an at-
tractant in a real-time cell analysis of migration. Under
these conditions, most of the uPAR would be cleaved as
shown in Fig. 1f. AT84-uPAR cells displayed a 1.4 fold
increase in migration compared to the AT84-EV cells at
24 h, and 1.6 fold at 48 h (p < 0.005)(Fig. 3c).
To analyse whether inhibiting uPA activity, and thus
also uPAR cleavage, would influence cell migration and
proliferation, AT84-uPAR cells were analysed for prolifer-
ation and migration in the presence of the uPA inhibitors
PAI-1 or BC11, and TGF-β1. None of these had any effect
on proliferation (Fig. 3d), but interestingly inhibiting uPA
activity using BC11 significantly reduced migration
(Fig. 3e, p=0.008). Although not statistically signifi-
cant, there was also a tendency towards reduction of
migration when PAI-1 was present. Not surprisingly,
as TGF-β1 has multiple effects on cells, a slight in-
crease in migration was induced, though not statisti-
cally significant.
Analysis of invasion using the leiomyoma invasion
model [60] showed that AT84-uPAR cells invaded more
deeply than AT84-EV cells (Fig. 3f ). Furthermore, inhib-
ition of uPA activity using the uPA inhibitor BC11 sig-
nificantly reduced tissue invasion by AT84-uPAR cells
(Fig. 3f and g). No reduction of invasion was observed in
the AT84-EV cells, even though both expression and ac-
tivation of uPA in these cells was equal to that of the
AT84-uPAR cells (see Fig. 1c and d). Taken together,
these results indicate that uPAR and uPA together in-
duce migration and invasion of the AT84 OSCC cells,
and inhibition of uPA activity reduces both migration
and invasion in an uPAR-dependent manner.
Soluble uPAR shed from mouse OSCC cells induce migration
in a paracrine manner
When human uPAR is cleaved between domains I and II
a chemotactic peptide sequence (SRSRY) that remains
on uPAR (II-III) may be revealed [61]. However, less is
known about whether the equivalent amino acid se-
quence in mouse uPAR, PQGRY [17], can stimulate mi-
gration. Both full-length and cleaved human uPAR can
be shed from the cell surface and have been found as
soluble forms, termed suPAR and suPAR (II-III), re-
spectively [28]. To analyse whether suPAR and suPAR
(II-III) were detectable in the conditioned medium from
AT84-uPAR cells, the serum-free conditioned medium
was concentrated, deglycosylated and analysed by
Western blotting (Fig. 4a). Both forms of suPAR were
found present in the concentrated conditioned medium,
however most of suPAR was full-length. Interestingly,
when plasminogen was added to cultured cells, this re-
sulted in markedly more suPAR (II-III) in the condi-
tioned medium, reflecting the ratio observed on the cell
surface as shown in Fig. 1h and further emphasizing the
role of plasmin in regulation of uPAR cleavage. SuPAR
could not be detected in the concentrated conditioned
medium from AT84-EV cells, nor in AT84-uPAR con-
centrated conditioned FBSM (Fig. 4b), as expected due
to serum-induced inhibition of phospholipases [62, 63].
To test whether mouse suPAR could function as a
chemoattractant as previously reported for human uPAR
[64], the conditioned SFM from AT84-EV and AT84-
uPAR cells was harvested and used as an attractant in a
migration assay using the AT84-EV cells (Fig. 4c). The
AT84-EV cells migrated to a significantly larger extent
towards the conditioned medium from the AT84-uPAR
(See figure on previous page.)
Fig. 2 TGF-β1 reduces uPAR cleavage through induced PAI-1 expression. a, f-h. Western blot analysis of whole cell lysates of cultured and stimulated
AT84-uPAR cells. Where indicated, cell lysates were either treated with PNGase F (+) or samples received the same treatment except that PNGase F was
omitted (−). Glycosylated uPAR is indicated as uPARglc. d-e. Western blot analysis of conditioned medium from equally seeded amounts of AT84-EV and
AT84-uPAR cells. a. Cells cultured in FBSM with or without 2 ng/ml active human TGF-β1 for 24 h. b-c. Total RNA from treated (TGF-β1) or untreated (Ctrl)
cells was isolated and the relative expression of uPAR mRNA (B) or uPA mRNA (C) was analysed using RT-qPCR. The error bars show the +SD. N = 3. d. Cells
cultured in SFM or FBSM and stimulated with 2 ng/ml TGF-β1 for 24 h as indicated and PAI-1 protein levels were analysed. Controls received either no
additives (−) or the TGF-β1 buffer (0). Positive control: recombinant mouse PAI-1 (rmPAI-1). e. AT84-uPAR cells cultured in either SFM or in FBSM. Cells were
either unstimulated (−) or stimulated (+) with 2 ng/ml TGF-β1 and/or 10 μM of the TGF-β1-inhibitor SB431542 as indicated. f. AT84-uPAR cells were
cultured for 24 h in FBSM and stimulated with 2 ng/ml TGF-β1 as indicated. g. Deglycosylated whole cell lysates from AT84-uPAR cells
cultured in SFM stimulated with 2 ng/ml TGF-β1 +/− the inhibitor SB431542 as indicated were analysed for uPAR protein levels. h. Cells were cultured
for 24- or 48 h in SFM, FBSM or TMEM. Cells were treated with 2 ng/ml TGF-β1 in 10% FBS as indicated. The LRP1 protein is indicated. Arrowhead
shows an unknown band
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cells compared to the medium from the AT84-EV cells,
suggesting that also mouse suPAR/suPAR (II-III) may
enhance migration of the AT84 OSCC cells in a para-
crine manner.
Discussion
We previously found that uPAR expression was up-
regulated at the tumour-stroma border in a mouse
model for OSCC [35]. Soluble factors derived from the
tumour microenvironment were shown to contribute to
the increased expression of uPAR, but were also impli-
cated in cleavage of the receptor. Cleavage of uPAR may
regulate its many functions related to migration and in-
vasion [28]. In the current study we aimed at analysing
the effect of TGF-β1 and uPA on uPAR cleavage and the
potential implications for cell proliferation, migration
and invasion.
Overexpressing uPAR in the AT84 cells was shown to
slightly increase the cells ability to migrate in 2D–cul-
ture (Fig. 3c). Moreover, inhibition of uPA activity with
the subsequent shift towards more full-length uPAR,
reduced both migration and invasion in a uPAR-
dependent manner (Fig. 3e and f), suggesting functional
relevance of the cleavage status of uPAR. It should how-
ever be kept in mind that uPA is one of the main activa-
tors of the broad-spectrum protease plasmin, which can
result in further activation of other proteases such as
MMPs [8]. Hence, by inhibiting uPA, the end result is
not simply a reduction in uPAR cleavage. Interestingly
though, inhibition of uPA activity in AT84-EV cells,
expressing equal levels of active uPA, had no effect on
invasion (Fig. 3f ). This indicates that uPA exerts its inva-
sion- and migration-promoting effects in concert with
uPAR. It has been shown that membrane bound uPAR
(II-III) can, at least in some types of human cells, stimu-
late migration through exposure of the SRSRY-peptide
located between domain I and II of human uPAR [61].
uPAR (II-III) interacts with formyl-peptide receptors
(FPRs), a type of G-protein coupled receptor (GPCR),
via the SRSRY peptide, resulting in increased migration
[27, 64–67]. In mouse uPAR, the corresponding amino
acid sequence is PQGRY [17], and less is known about
whether this mouse uPAR peptide encompasses similar
functionality. The closely related rat uPAR peptide,
PRGRY, has been reported to induce chemotaxis and
cytoskeletal rearrangement [68]. The amino acids R and
Y in the peptides are highly conserved and it has been
shown that Y92 in human uPAR is the essential amino
acid in triggering activation of the GPCR downstream
effectors p56/59(hck) [27, 69]. Both GPI-anchored hu-
man uPAR (II-III) and suPAR (II-III) are reported to in-
duce migration [28]. Both of these fractions could
potentially contribute to the migration and invasion seen
in Fig. 3. However we could only detect suPAR in the
serum free conditioned medium and not the FBSM
(Fig. 4b). Hence, the uPAR-induced migration seen in
Fig. 3, which was performed in the presence of FBS, is
most likely induced through the membrane bound form.
We also tested whether media containing uPAR shed
from the cell surface could induce migration. uPA-
induced uPAR cleavage is performed most efficiently
when uPAR is GPI-anchored to the cell surface [20, 23],
hence uPAR is probably cleaved before it is shed. In sup-
port of this, the levels of suPAR (II-III) and suPAR (I-III)
reflected the levels observed on the cell surface (Figs. 4a
and 1h). Gilder et al. recently showed that suPAR may
function in a paracrine manner, enhancing migration
and invasion of glioblastoma cells [70]. Furthermore, the
levels of suPAR, suPAR (II-III) and suPAR (I) in bio-
logical fluids have all been linked to poor prognosis of
several different cancer types [32, 71, 72]. To the best of
our knowledge it has not previously been shown that
mouse suPAR can induce chemotaxis. An analysis of the
serum free conditioned medium revealed that the major-
ity of the shed uPAR was full-length (Fig. 4a). Using the
conditioned medium as an attractant during cell migra-
tion clearly induced AT84 cell migration compared to
medium without suPAR (Fig. 4c). Hoyer-Hansen et al.
used an SRSRY-recognising antibody and showed that
the SRSRY-peptide could not be detected when uPAR
(See figure on previous page.)
Fig. 3 Inhibition of uPA-activity reduces migration and invasion in an uPAR-dependent manner. a-e. Real-time cell analysis of proliferation and migration
of the AT84-EV and AT84-uPAR cells using the xCELLigence system. N = 3, where each experiment had two technical replicates. The y-axis shows the
arbitrary “cell index” value based on cell adhesion induced impedance. Error bars show the ±SD. Student T-test; * p < 0.05, ** p < 0.005, *** p < 0.001. Fold
difference was calculated using the mean values. a. One representative proliferation experiment. The standard deviation is based on the two technical
replicates. The two vertical black lines show the 24- and 48 h points. Purple line = AT84-uPAR, green line = AT84-EV. Flat purple line = negative control; no
cells added. b. Cell index values collected from three separate proliferation experiments at 24- and 48 h. c. Cell index values collected from three separate
migration experiments at 24- and 48 h. d. Proliferation of AT84-uPAR cells treated with 10 μM BC11, 10 nM rmPAI-1 or 2 ng/ml TGF-β1 for 48 h. Controls
received no additives. e. Migration of AT84-uPAR cells treated with 10 μM BC11, 10 nM rmPAI-1 or 2 ng/ml TGF-β1 for 48 h. Controls received no additives.
f. AT84-EV and AT84-uPAR cells invaded the tissue of the leiomyoma invasion model for 7 days with or without the uPA-inhibitor BC11 hydrobromide
present (+BC11). Controls received no additives (Ctrl), N = 3. Invasion depth was determined using at least 6 measurements per tissue section. The bars
show the mean values of the three discs and the error bars show the ±SEM (N = 3). g. Representative tissue sections of invading AT84-uPAR cells were
immunohistochemically stained for uPAR (right panels). Positive uPAR staining is seen as brown colour, counterstained with haematoxylin. Images were
recorded at 20 x magnification
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was solubilised in its full-length version [20]. Hence, the
chemotaxis inducing SRSRY-sequence of human uPAR
is most probably not exposed on soluble full-length
uPAR. Though the amount of suPAR (II-III) in the con-
ditioned medium used here was very low compared to
the full-length uPAR, only very low molar concentra-
tions of the peptide are needed to induce migration [64].
As previously mentioned, mouse uPAR does not contain
this exact SRSRY-sequence, and whether it is the
PQGRY-sequence of mouse uPAR that induces the mi-
gration that we observe, or whether it is induced
through another pathway is an interesting topic for fu-
ture investigations. Nevertheless, the finding that media
containing mouse suPAR has chemotaxic capabilities
shows that expression of mouse uPAR in AT84-cells is a
good model for further investigations of uPAR cleavage
in vivo as it resembles human uPAR also in this respect.
We previously found that soluble factors from the
TME of the leiomyoma tissue up-regulated uPAR ex-
pression and glycosylation and influenced uPAR cleavage
[35]. Through analysis of the soluble TME fraction,
TGF-β1 was found to be a major constituent [50]. We
could now show that TGF-β1 is involved in regulating
uPAR cleavage through stimulated PAI-1 secretion
(Fig. 2). TGF-β signalling is either transmitted through
SMADs, known as the canonical pathway, or through
SMAD-independent (non-canonical) pathways, including
tumour-necrosis factor (TNF) receptor-associated factor 4
(TRAF4) and TRAF6, p38 mitogen-activated protein kin-
ase (p38 MAPK), RHO, AKT and ERK. Complicating this
is the possibility that TGF-β signalling may be perturbed
by other interacting pathways, epigenetic mechanisms,
microRNAs and by corepressors [73, 74]. Interestingly,
AT84 cells stimulated with TGF-β1 showed no change in
proliferation at 48 h, but clearly increased PAI-1 expres-
sion. PAI-1 expression could be inhibited by SB431542, an
inhibitor known to specifically inhibit the TβR-I proteins
activin receptor-like kinases (ALK) -4, −5 and −7 [75],
showing that the TGF-β1 receptor functions are intact.
SMADs −2 and −3 are substrates for ALK4, −5 and −7,
further transmitting the signal to the nucleus and initiat-
ing target gene transcription [75]. Why AT84-uPAR cell
proliferation was unaffected by TGF-β1 stimulation even
though the TGF-β1 receptor functions normally is an in-
teresting target for future studies. Several different cell
types in the TME secrete TGF-β1, which also functions as
one of the major activators of fibroblasts, turning the
fibroblasts into CAFs/myofibroblasts [76, 77]. Once acti-
vated, CAFs can furthermore secrete elevated levels of
TGF-β1 [38, 78], which can be deposited in the TME. This
could lead to increased secretion of PAI-1 from tumour
cells, in turn inhibiting uPA activity and reducing uPAR
cleavage. The end result being more full-length uPAR
compared to cleaved uPAR. A reduction in uPA activity
would most likely also reduce activation of plasmin and
thus the overall proteolytic activity, contradicting the no-
tion that TGF-β1 drives cancer progression. However, the
TME is dynamic and stromal cells can be unequally dis-
tributed [79]. Furthermore, full-length uPAR interacts
with a different subset of cell surface receptors compared
to cleaved uPAR, enabling cancer cells to switch binding
partners, modulate receptor functions, adhesion, migra-
tion and proteolytic activity in relation to TGF-β1 status
Fig. 4 Soluble uPAR shed from mouse OSCC cells induce migration.
a-b. Western blot analysis of uPAR protein levels in concentrated
conditioned medium from AT84-EV and AT84-uPAR cells. a. Conditioned
medium from cells cultured in SFM or SFM containing 10 nM plasminogen
(plg) as indicated. The conditioned medium was concentrated from 2 ml to
110 μl for both samples, and deglycosylated using PNGase F. b. Conditioned
medium from cells cultured in SFM or in FBSM was concentrated from 2 ml
to 350 μl for each sample. A whole cell lysate sample of AT84-uPAR cells
was used as a positive control. The two indicated FBSM samples are
replicates. Glycosylated suPAR is indicated as suPARglc. c. Non-concentrated
conditioned medium from AT84-EV (EV medium) and AT84-uPAR cells
(uPAR-medium) was used as an attractant for the AT84-EV cells
in a real-time cell migration analysis using the xCELLigence system.
N = 3, where each experiment had two technical replicates, and the
error bars represent the standard error of mean (±SEM) based on three
separate experiments
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[26, 27]. In oral cancer, α-SMA positive myofibroblasts are
present to a greater extent in more invasive OSCC than in
low-invading OSCC, and completely absent in normal tis-
sue [80]. Similarly, TGF-β1 was not found expressed in
normal oral mucosa, but increased expression was seen in
oral leukoplakia and OSCC, including its reactive stroma
[12, 13]. Interestingly, our previous findings show that up-
regulated expression of PAI-1 (a target gene for TGF-β1)
and uPAR in early stage OSCC correlated with poor dis-
ease specific survival [11]. Hence, further studies on the
role of these components in uPAR cleavage are warranted
in order to elucidate their role in OSCC progression.
Conclusions
Taken together, these results demonstrate that OSCC
cellular behaviour may be regulated not only through
the levels of uPAR, but also through the balance be-
tween full-length uPAR and uPAR (II-III) present on
cancer cells, and that TGF-β1 may control these events
through the regulation of PAI-1 expression and subse-
quent uPA inhibition.
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